Clinical Trial Update: Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update evaluates pembrolizumab in patients with stage IV inflammatory breast cancer or triple-negative breast cancer who achieved cl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Edema, Erythema | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-02